Any vaccine that produces broad immunity against influenza A would be a significant improvement over the current strain-specific vaccines that must be produced anew each year. Additionally, this vaccine would be produced synthetically, which is a major improvement over the current methods of growing influenza vaccine in fertilized eggs.

U.S. Patent Nos. 7,354,589; 7,740,860 and 7,527,798; and international patents.

This technology is available for exclusive license.

Mozdzanowska, et al., Vaccine, 21, 2616-2626. 2003.